Monaco Asset Management
BMRN icon

Monaco Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Monaco Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.4M Buy
239,937
+55,000
+30% +$3.46M 1.76% 15
2026
Q2 		$10.6M Buy
184,937
+154,937
+516% +$8.49M 0.84% 19
2026
Q1 		$1.69M Buy
+30,000
New +$1.75M 0.31% 40

Other funds holding BMRN

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Monaco Asset Management's BMRN Position: Q3 2026 in Review

Monaco Asset Management increased its BioMarin Pharmaceuticals (BMRN) stake by 30% in Q3 2026, buying an estimated $3.46M and bringing the position to 239,937 shares worth $14.4M. The position accounts for 1.76% of the portfolio, ranked #15.

Monaco Asset Management first reported a position in BMRN in Q1 2026 and has held it in 3 quarters since. 434 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Monaco Asset Management held 239,937 shares of BioMarin Pharmaceuticals worth $14.4M as of Q3 2026.
  • Monaco Asset Management bought 55,000 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $3.46M.
  • BioMarin Pharmaceuticals made up 1.76% of Monaco Asset Management's portfolio in Q3 2026, its #15 holding.
  • Monaco Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 434 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Monaco Asset Management's 13F filing for Q3 2026, filed 9 Nov 2026.